Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
Follow VRAX
Virax Biolabs Group Limited (VRAX) Altman Z-score
Virax Biolabs Group Limited's Altman Z-score for fiscal 2026 is −5.30, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −5.30 | (0.26) |
| FY2025 | −5.04 | 0.15 |
| FY2024 | −5.19 | (7.53) |
| FY2023 | 2.33 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.74 | — | 0.89 | |
| Retained earnings / total assets | (3.56) | — | −4.98 | |
| EBIT / total assets | (0.77) | — | −2.54 | |
| Market value of equity / total liabilities | 2.21 | — | 1.33 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −5.30 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −4.14 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| PPBT Purple Biotech Ltd. Sponsored ADR compare | 5.5× |
| VRAX Virax Biolabs Group Limited | −5.3× |
| NTBLQ Notable Labs, Ltd. compare | −6.7× |
| WINT Windtree Therapeutics, Inc. compare | −7.0× |
| MTNB Matinas Biopharma Holdings, Inc. compare | −11.9× |
| CLSDQ Clearside Biomedical, Inc. compare | −22.1× |
| BRTX Biorestorative Therapies, Inc. compare | −71.0× |
| KAPA Kairos Pharma, Ltd. compare | — |
| BPTSY Biophytis SA Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets